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Abstract 
The BIN1 gene encodes a set of BAR adapter 
proteins generated by alternate RNA splicing which 
function in membrane and actin dynamics, cell 
polarity and stress signaling. In cancer cells, BIN1 
functions as a tumor suppressor gene and it is 
commonly silenced or misspliced during malignant 
progression. Genetic investigations in fission yeast, 
flies, mice and human cells suggest that BIN1 
adapter proteins exert a 'moonlighting' function in 
the nucleus, integrating cell polarity signals 
generated by actin and vesicle dynamics with 
central regulators of cell cycle control, apoptosis, 
and immune surveillance (adapted from Prendergast 
et al., 2009). 
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The human BIN1 gene is encoded by at least 16 
exons spanning at least 59258 bps at chromosome 
2q14-2q21 (nucleotides 127522078-127581334). 
The murine Bin1 gene is similarly sized but 
localized to a syntenic locus on mouse chromosome 
8 (Wechsler-Reya et al., 1997). 
Transcription 
The Bin1 promoter is rich in CpG methylation 
residues and transcription of the gene produces 
more than 10 alternative transcripts that are from 
2075 to 2637 bp mRNA in size: isoform 1 (2637 
bp), isoform 2 (2508 bp), isoform 3 (2376 bp), 
isoform 4 (2333 bp), isoform 5 (2412 bp), isoform 
6 (2289 bp), isoform 7 (2283 bp), isoform 8 (2210) 
bp, isoform 9 (2165bp), and isoform 10 (2075 bp). 
Isoforms 9 and 10 are ubiquitous in expression. 
Isoform 8 is expressed specifically in skeletal 
muscle.  
Isoforms 1-7 are expressed predominantly in the 
central nervous system. An aberrant isoform has 
been reported to be expressed specifically in tumor 





Bin1 contains N-terminal BAR 
(Bin1/Amphihysin/Rvs) domain with predicted 
coiled-coil structure and a C-terminal SH3 domain 
(Sakamuro et al., 1996). Bin1 encodes proteins of 
409 to 593 amino acids; isoform 1 (593 aa), isoform 
2 (550 aa), isoform 3 (506 aa), isoform 4 (497 aa), 
isoform 5 (518 aa), isoform 6 (482 aa), isoform 7 
(475 aa), isoform 8 (454 aa), isoform 9 (439 aa), 
and isoform 10 (409 aa). 
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At least 10 alternate protein isoforms of Bin1 are expressed in different tissues. Isoforms 9 and 10 are ubiquitous. Isoform 8 is 
muscle-specific. Isoforms 1-7 are expressed predominantly in the central nervous system. Two tumor-specific isoforms include 
an exon termed 12A that is normally spliced into Bin1 mRNA only with other exons expressed in the central nervous system. 
These tumor-specific isoforms occur commonly in cancer and they represent loss of function with regard to tumor suppression 
activity and nuclear localization capability. BAR, BAR domain; SH3, SH3 domain; MBD, Myc binding domain; CLAP, clathrin-
associated protein binding region; PI, phosphoinositide binding region. Exons are numbered by reference to Wechsler-Reya et 
al. (1997). 
 
Isoform 10 is the smallest and isoform 1 is the 
largest in size. Also, Bin1 has predicted molecular 
weight of 45432 to 64568 Da; isoform 1 (64568 
Da), isoform 2 (59806 Da), isoform 3 (55044 Da), 
isoform 4 (54817 Da), isoform 5 (56368 Da), 
isoform 6 (52889 Da), isoform 7 (51606 Da), 
isoform 8 (50054 Da), isoform 9 (48127 Da), and 
isoform 10 (45432 Da). Isoforms 9 and 10 are 
ubiquitous in expression. Isoform 8 is expressed 
specifically in skeletal muscle. Isoforms 1-7 are 
expressed predominantly in the central nervous 
system. These 10 different splice isoforms differ 
widely in subcellular localization, tissue 
distribution, and ascribed functions, with isoforms 
1-7 predominantly cytosolic but isoforms 8-10 
found in both the nucleus and/or cytosol of certain 
cell types (Sakamuro et al., 1996; Muller et al., 
2003). Recent studies demonstrated that the coiled-
coil BIN1 BAR peptide encodes a novel BIN1 MID 
domain, through which BIN1 acts as a MYC-
independent cancer suppressor (Lundgaard et al., 
2011). 
Expression 
Bin1 is widely expressed (Wechsler-Reya et al., 
1997; Chapuis et al., 2013). Patterns of isoform 
expression are noted above in the diagram legend. 
Localisation 
Bin1 is localized both in nuclear and cytosolic in 
the cerebral cortex and cerebellum of brain. Bin1 is 
localized mainly in nuclear in bone marrow cells 
whereas it is localized mainly in cytosolic in 
peripheral lymphoid cells. Bin1 is nuclear or 
nucleocytosolic in basal cells of skin, breast, or 
prostate, whereas it is cytosolic or plasma 
membrane localized in gastrointestinal cells 
(DuHadaway et al., 2003). In cardiac muscles Bin1 
generate T-tubules and also designates T-tubules as 
the appropriate site for delivery of L-type calcium 
channels (Hong et al., 2010). 
Function 
Bin1 encodes members of the BAR 
(Bin/Amphiphysin/Rvs) adapter family which have 
been implicated in membrane dynamics, such as 
vesicle fusion and trafficking, specialized 
membrane organization, actin organization, cell 
polarity, stress signaling, transcription, 
immunomodulation and tumor suppression. BAR 
adapter proteins are now recognized to be part of a 
larger superfamily of structurally related proteins 
that includes the so-called F-BAR and I-BAR 
adapter proteins (Ren et al., 2006; Prendergast et 
al., 2009). 
Membrane binding and tubulation: The Bin1 
BAR domain can mediate binding and tubulation of 
curved membranes (Lee et al., 2002; Wu et al., 
2014). Crystal structures of the BAR domains from 
human BIN1 and its fruit fly homolog reveal a 
dimeric banana-shaped 6-alpha-helix bundle that 
can nestle against the charged head groups on a 
curved lipid bilayer. Structural studies implicate 
specific alpha-helices in tubulation activity. 
Biochemical analyses implicate Bin1 in vesicle 
fission and fusion processes, with the SH3 domain 
providing an essential contribution to these 
processes through the recruitment of dynamins 
(Ren et al., 2006). 
Vesicle trafficking: Bin1 is implicated in 
endocytosis and intracellular endosome traffic 
through interactions with Rab5 guanine nucleotide 
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exchange factors (Rab GEFs) and the sorting nexin 
protein Snx4. Complexes of neuronal Amph-I with 
neuron-specific isoforms of Bin1 (Amph-II) have 
been implicated in synaptic vesicle recycling in the 
brain. Genetic studies of the Bin1 homolog in 
budding yeast indicate an essential role in 
endocytosis, however, this role appears to be non-
essential for homologs in fission yeast, fruit flies, 
and mice (Leprince et al., 2003). 
Cell polarity: Genetic analyses of the Bin1 
homologs in yeast and fruit flies suggest a 
integrative function in cell polarity, possibly 
mediated by effects on actin organization and 
vesicle trafficking. In budding yeast, the Bin1 
homolog RVS167 lies at a central nodal point for 
integrating cell polarity signaling (Balguerie et al., 
1999). Genetic ablation of the Bin1 homolog in 
fruit flies causes mislocalization of the cell polarity 
complex Dlg/Scr/Lgl, normally localized to the 
tight junction, that is implicated in epithelial 
polarity and suppression of tumor-like growths in 
flies (Humbert et al., 2003). 
Transcription: Ubiquitous and muscle-specific 
isoforms of Bin1 that can localize to the nucleus 
can bind to c-Myc and suppress its transcriptional 
transactivation activity (Elliott et al., 1999). 
Tethering the BAR domain of Bin1 to DNA is 
sufficient to repress transcription. Genetic studies in 
fission yeast demonstrate that the functional 
homolog hob1+ is essential to silence transcription 
of heterochromatin at telomeric and centromeric 
chromosomal loci by supporting a Rad6-Set1 
pathway of transcriptional repression (Ramalingam 
and Prendergast, 2007). 
Muscle function: Mutations of the human BIN1 
gene are associated with centronuclear myopathy, a 
disorder marked by severe muscle weakness (Nicot 
et al., 2007; Wu et al., 2014). In skeletal muscle, 
Bin1 localizes to T tubules where it appears to 
support ion flux (Lee et al., 2002; Butler et al., 
1997). In vitro studies of terminal muscle 
differentiation implicate Bin1 in myoblast cell cycle 
arrest and fusion during tubule formation 
(Wechsler-Reya et al., 1998). 
Cardiac function: Mouse genetic studies indicate 
that Bin1 is required for cardiac development 
(Hong et al., 2010). Bin1 levels decreases in failing 
hearts and low level of plasma Bin1 correlates with 
heart failure and predicts arrhythmia in patients 
with arrhythmogenic right ventricular 
cardiomyopathy (Hong et al., 2012). 
Cognition and Memory: Bin1 is one of the 
candidate genes involved in Alzheimer's disease. 
Bin1 is the most important risk locus for late onset 
Alzheimer's disease. Bin1 affects AD risk primarily 
by modulating tau pathology (Tan et al., 2013; 
Kingwell, 2013; Chapius et al., 2013). 
Immunomodulation and Barrier Function: Bin1 
is a genetic modifier of experimental colitis that 
controls the paracellular pathway of transcellular 
ion transport regulated by cellular tight junctions 
(Chang et al., 2012). 
Apoptosis and Senescence: Bin1 is crucial for the 
function of default pathways of classical apoptosis 
or senescence triggered by the Myc or Raf 
oncogenes in primary cells (Prendergast et al., 
2009). In human tumor cells, enforced expression 
of Bin1 triggers a non-classical program of cell 
death that is caspase independent and associated 
with activation of serine proteases (Elliott et al., 
2000). 
Tumor suppression: Attenuation of Bin1 function 
by silencing or missplicing is a frequent event in 
multiple human cancers including breast, prostate, 
skin, lung, and colon cancers (Sakamuro et al., 
1996; Ge et al., 2000b). In breast cancer, attenuated 
expression of Bin1 is associated with increased 
metastasis and poor clinical outcome (Chang et al., 
2007b). In human tumor cells, ectopic expression of 
ubiquitous or muscle Bin1 isoforms causes growth 
arrest or caspase-independent cell death 
(Prendergast et al., 2009). A Bin1 missplicing event 
that occurs frequently in human cancers is sufficient 
to extinguish these activities. In primary rodent 
cells, Bin1 inhibits oncogenic co-transformation by 
Myc, adenovirus E1A, or mutant p53 but not SV40 
T antigen (Elliott et al., 1999; Elliott et al., 2000). 
Mouse genetic studies establish that loss of Bin1 
causes lung and liver cancers during aging (Chang 
et al., 2007a). In mice where breast or colon tumors 
are initiated by carcinogen treatment, Bin1 deletion 
causes progression to more aggressive malignant 
states (Chang et al., 2007b). Oncogenically 
transformed cells lacking Bin1 exhibit reduced 
susceptibility to apoptosis and increased 
proliferation, invasion, immune escape, and tumor 
formation (Muller et al., 2004, Muller et al., 2005). 
Activation of metalloproteinase MMP9 and 
immunosuppressive enzyme indoleamine 2,3-
dioxygenase (IDO) have been implicated 
respectively in invasion and immune escape caused 
by Bin1 loss (Chang et al., 2007b). Cisplatin is the 
most important and efficacious chemotherapeutic 
agent for the treatment of advanced gastric cancer. 
The oncoprotein c-Myc suppresses bridging 
integrator 1 (BIN1), thereby releasing poly(ADP-
ribose)polymerase 1, which results in increased 
DNA repair activity and allows cancer cells to 
acquire cisplatin resistance (Tanida et al., 2012). 
Null phenotype in mouse: Bin1 knockout mice are 
perinatal lethal owing to myocardial hypertrophy 
where myofibrils of ventricular cardiomyocytes are 
severely disorganized (Muller et al., 2003). Genetic 
mosaic mice display increased susceptibility to 
inflammation, premalignant lesions in prostate and 
pancreas, and formation of liver and lung 
carcinoma. Female mosaic mice exhibit increased 
fecundity during aging. Tissue-specific gene 
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ablation in skin or breast facilitates carcinogenesis 
(Chang et al., 2007a). 
Homology 
The longest Bin1 alternate splice variant in human 
brain exhibits 71% amino acid sequences similarity 
and 55% amino acid sequence identity with 
amphiphysin-I (amph-I) (Ren et al., 2006). Bin1 is 
also closely related to the mammalian amphiphysin-
like genes Bin2 and Bin3 (Routhier et al., 2003). 
Genetic homologs of Bin1 that exist in budding and 
fission yeast (RVS167 and hob1+) and in fruit flies 
(amphiphysin) are well-characterized (Ren et al., 
2006; Prendergast et al., 2009). 
Mutations 
Note 
Epigenetics: Attenuated expression or missplicing 
occurs in many cases of breast, prostate, lung, skin, 
brain and colon cancers. Expression analyses have 
identified Bin1 missplicing as among the most 
common missplicing events occurring in cancer 
(Chang et al., 2007). 
Germinal 
Germ-line mutations leading to nonsynonymous 
alterations in Bin1 have been associated with the 
familial muscle weakness disorder centronuclear 
myopathy, a disorder characterized by abnormal 
centralization of nuclei in muscle fibers. Two 
missense alterations the BAR domain that have 
been identified as loss of function mutations for 
membrane binding are K35N and D151N (Nicot et 
al., 2007). Another mutation that has been 
identified, K575X, generates a prematurely 
terminated Bin1 protein implicated in loss of 
function (Nicot et al., 2007). 
Somatic 
Loss of heterozygosity of Bin1 in cases of 
metastatic prostate cancer has been reported in the 
absence of mutation of the remaining allele. 
Infrequent instances of gene deletions have been 
reported in breast tumor cell lines (Chang et al., 




Breast cancer is the second leading cause of cancer 
death in women following lung cancer. Bin1 
expression is attenuated significantly in >50% of 
cases of malignant breast cancer by 
immunohistochemical or RT-PCR analysis (Ge et 
al., 2000a). Reduced levels of Bin1 are correlated to 
increased nodal metastasis and reduced survival in 
low or middle grade carcinomas.  
Mouse genetic studies indicate that Bin1 is non-
essential for mammary gland development but that 
it is needed for the rapid kinetics of ductolobular 
remodeling during pregnancy and weaning.  
In mammary gland tumors initiated by the ras-
activating carcinogen 7,12-dimethylbenzanthracene 
(DMBA), Bin1 loss strongly accentuates the 
formation of poorly differentiated tumors 
characterized by low tubule formation, high mitotic 
indices, and high degree of nuclear pleomorphism. 
Bin1 loss facilitates tumor progression at several 
intrinsic levels, including increased proliferation, 
survival, and motility of mouse mammary epithelial 
cells (MMECs) established from DMBA-induced 
tumors (Chang et al., 2007b). 
Lung cancer 
Oncogenesis 
Lung cancer is a leading cause of death from 
cancer.  
Bin1 expression has been reported to be attenuated 
significantly in cases of lung adenocarcinoma by 
immunohistochemical analysis.  
Mouse genetic studies demonstrate that Bin1 loss is 
associated with formation of lung adenocarcinoma 
during aging, indicating that Bin1 attenuation 
drives disease incidence (Chang et al., 2007a). 
Colon cancer 
Oncogenesis 
Colorectal cancer is the third most common cancer 
in the developed world.  
Bin1 expression has been reported to be attenuated 
significantly in ~50% of cases of colon cancer by 
Immunohistochemical analysis.  
Mouse genetic studies indicate that, in colon tumors 
initiated by treatment with the carcinogen 
dimethylhydrazine (DMH), Bin1 loss facilitates 
progression to more aggressive tumors with a 
higher multiplicity (Chang et al., 2007a). 
Skin cancer 
Oncogenesis 
Skin cancer is the most common form of cancer. 
Basal cell cancer and squamous cell cancer are 
most common and treatable whereas melanoma is 
less common and deadlier. Studies of human 
melanoma revealed that Bin1 is inappropriately 
expressed as tumor cell-specific isoforms that 
include exon 12A, which is alternately spliced into 
isoforms found in the central nervous system but 
not normally on its own in melanocytes or other 
non-neuronal cells. This aberrant splicing event 
abolishes the tumor suppressor functions of Bin1 
based on the loss of its anti-oncogenic and 
programmed cell death inducing activities in 
oncogenically transformed cells and melanoma 
cells. Mouse genetic studies indicate that Bin1 loss 
facilitates skin carcinogenesis (Ge et al., 1999). 
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Prostate cancer 
Oncogenesis 
Prostate cancer is the leading cause of death in men 
older than 55 years of age. Loss of heterozygosity 
of the human BIN1 gene has been reported in ~40% 
of cases of metastatic prostate cancer. Bin1 is 
expressed in most primary tumors, even at slightly 
elevated levels relative to benign tissues, but it is 
frequently grossly attenuated in expression or 
inactivated by aberrant splicing in metastatic 
tumors and androgen-independent tumor cell lines. 
Ectopic expression suppresses the growth of 
prostate cancer cell lines in vitro. Mouse genetic 
studies indicate that Bin1 loss is associated with an 
increased incidence of prostate inflammation, 
atrophy, hypertrophy, and intraepithelial neoplasia 
during aging (Ge et al., 2000b). 
Neuroblastoma 
Oncogenesis 
Neuroblastoma (NB) is the most common solid 
tumor of childhood and is responsible for 15% of 
childhood cancer-related deaths. Bin1 expression is 
grossly reduced in MYCN amplified and metastatic 
NB compared with MYCN single-copy and 
localized NB as evaluated by real-time RT-PCR. 
Enforced expression of Bin1 in MYCN amplified 
human NB cell lines markedly inhibits colony 
formation (Hogarty et al., 2000). 
Cardiomyopathy 
Note 
Dilated cardiomyopathy (DCM) is a leading cause 
of heart failure with as much as >25% of cases of 
familial etiology. A whole genome screen 
performed in a three-generation family with 12 
affected individuals with autosomal dominant 
familial DCM defined linkage to chromosome 
2q14-q22 where the human BIN1 gene is located 
(Jung et al., 1999). While BIN1 was not specifically 
identified as the germane locus, mouse studies 
indicate that genetic ablation causes 
cardiomyopathy during development. Moreover, in 
mice where Bin1 is ablated after birth in a tissue-
specific manner in cardiomyocytes, a progressive 
cardiomyopathy develops consistent with the 
possibility that Bin1 loss of function may be a 
cause of DCM (Muller et al., 2003). 
Centronuclear myopathy 
Note 
Germ-line mutations of Bin1 are associated with 
formation of this rare familial disorder 
characterized by abnormal centralization of nuclei 
in muscle fibers and severe muscle weakness (Nicot 
et al., 2007; Smith et al., 2014). In five affected 
individuals studied from three non-sanguineous 
families, two mutations extinguishing the 
membrane binding activity of the BAR domain 
were identified along one mutation causing a 




Mouse genetic studies indicate that Bin1 loss 
increases the general incidence of chronic 




Mouse genetic studies indicate that mosaic loss of 
Bin1 increases reproductive physiology during 
aging.  
Specifically, female mosaic mice exhibit extended 
fecundity during aging, retaining reproductive 
capability ~6 months longer than control mice 
(Chang et al., 2007a). 
Alzheimer's disease 
Note 
BIN1 transcript levels are increased in AD brains 
(Tan et al., 2013). Genome-wide association studies 
(GWAS) have identified the BIN1 gene as the most 
important genetic susceptibility locus in 
Alzheimer's disease (AD) after APOE. Decreased 
expression of the Drosophila BIN1 suppress Tau-
mediated neurotoxicity. Tau and BIN1 has been 
demonstrated to colocalize and interact in human 
neuroblastoma cells and in mouse brain (Chapuis et 
al., 2013; Kingwell, 2013). 
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